Latest Artificial Intelligence News

BKI Investment Company Limited reported a steady financial performance for FY2025, raising its ordinary dividend by 1% to 7.90 cents per share. The company remains confident in maintaining dividends in FY2026, supported by a diversified portfolio and positive economic outlook.

Axiom Properties has secured $1.4 million through an equity placement and plans a strategic rebrand to Axtec, aiming to accelerate growth in real estate technology. Additional convertible note financing is proposed to strengthen the balance sheet further.

OMG Group has completed a strategic integration with Shiperoo, enhancing its supply chain to meet rising demand from major Australian retailers and ecommerce channels. This move supports recent product expansions and aims to drive cost efficiencies and scalability.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

PainChek Limited has secured its first US customer, Jewish Home Family, just days after receiving FDA De Novo clearance for its AI-powered pain assessment app, marking a significant step into the $100 million US aged care market.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Hiremii Group has successfully raised $650,000 through an oversubscribed placement, underscoring strong investor confidence as it pushes forward with commercialising its AI-driven recruitment platform.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

DroneShield launches its largest AI software update yet, enhancing drone detection and disruption capabilities with doubled processing power and expanded databases.

Redox Limited reported a 9.4% increase in sales revenue for FY25 despite challenging global conditions, while declaring a robust dividend payout that exceeds its policy. The company’s strategic focus on specialty chemicals, operational expansion, and ESG commitments positions it well for continued growth.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.